Pfizer CEO Albert Bourla has said that they expect to submit the late-stage coronavirus vaccine results by the end of October this year.
The race for coronavirus vaccine is heating up with as many as seven candidates reaching the last stage of clinical trials. U.S. drugmaker Pfizer's Chief Executive Albert Bourla said in an online briefing that it had enrolled 23,000 volunteers in the phase three trial that began in late July, and expected to include up to 30,000 participants between the ages of 18 and 85 across 120 sites globally. He announced that if the trials are successful, they wish to submit for the final regulatory approval as early as October. Pfizer’s vaccine is one of three backed by the U.S. government that’s currently in late-stage testing.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.